Bio-Techne Corporation

“Bio-Techne possesses a durable, citation-embedded moat in validated reagents and a credible spatial biology growth vector, but the stock at $52.73 and 24x forward earnings prices in a full trough recovery with no margin of safety; add NIH/federal funding risk as a plausible multi-year headwind and the risk/reward does not justify action today — the right entry is $40-45 where uncertainty is compensated.”